An­a­lysts project a big spike in COPD mar­ket as new drugs ar­rive; Valeant rais­es $930M in lat­est as­set sale

→  The COPD drug mar­ket is ex­pect­ed to grow dra­mat­i­cal­ly over the next decade, hit­ting $14.1 bil­lion by 2025, ac­cord­ing to Glob­al­Da­ta.  It was $9.9 bil­lion in 2015. The growth will be fu­eled by in­creased di­ag­noses as well as new bron­chodila­tor drug class­es and an­ti-eosinophilic bi­o­log­ics.

→  Valeant is sell­ing iN­o­va for $930 mil­lion. The com­pa­ny is sell­ing off as­sets in an at­tempt to re­duce large piles of debt ac­quired un­der pre­vi­ous CEO Mike Pear­son as he went on a deal-mak­ing spree. Pear­son was re­placed by Joseph Pa­pa last year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN